Tagrisso (Osimertinib)

Tagrisso (Osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). This targeted therapy is designed to block specific EGFR mutations that drive the growth and spread of cancer cells, providing a more precise and effective treatment approach compared to conventional chemotherapy.

Tagrisso is widely used as a first-line treatment for patients with advanced or metastatic EGFR-mutated NSCLC and is also indicated for adjuvant treatment following tumor resection in eligible patients. In addition, it has demonstrated effectiveness in patients whose cancer has developed resistance to earlier-generation EGFR inhibitors due to specific resistance mutations.

Administered orally as a once-daily tablet, Tagrisso offers convenience and flexibility while delivering clinically proven benefits, including prolonged progression-free survival and improved overall survival in many patients. Its ability to penetrate the central nervous system also makes it an important treatment option for patients with brain metastases associated with EGFR-mutated lung cancer.

As a leading precision oncology medicine, Tagrisso represents a significant advancement in the treatment of lung cancer by combining targeted action, proven efficacy, and improved tolerability. It continues to play a vital role in personalized cancer care, helping healthcare professionals provide effective treatment tailored to the genetic profile of each patient’s disease.